jpd459/healthver_resplit huggingface dataset:
Question: are there any drugs that work for SARS-CoV or SARS-CoV-2 in animals?
Claim: As several FDA-approved or repurposed drugs are being tested as antiviral candidates at clinics without sufficient information, rapid preclinical animal studies should proceed to identify therapeutic drug candidates with strong antiviral potential and high safety prior to a human efficacy trial.
Evidence: There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. 
Verdict: Neutral
Evidence: When used for prophylaxis or treatment neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. In conclusion, our preclinical animal studies do not support the use of HCQ in prophylaxis/treatment of COVID-19.
Verdict: Neutral
Evidence: There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. 
Verdict: Neutral
Evidence: At this point, the data here presented on hydroxychloroquine either alone or combined with azithromycin (together with previously reported in vivo data in macaques and ferrets) provide no scientific basis for further use of the drug in humans.
Verdict: Neutral
Question: how does the coronavirus respond to changes in the weather
Claim: Cold weather kills coronavirus 2019 and 13 other COVID-19
Evidence: Preliminary observations from our team and others suggest that temperature and climatological factors could influence the spread of this novel coronavirus
Verdict: Refutes
Evidence: COVID-19, due to its regular flu-like symptoms, is also expected to show similar seasonality and subside as the global temperatures rise in the northern hemisphere with the onset of spring
Verdict: Refutes
Evidence: the temperature changes retarded the growth rate and found that -6.28{degrees}C and +14.51{degrees}C temperature is the favorable range for COVID-19 growth
Verdict: Refutes
Evidence: In the southern cities, the ambient temperature and air pollution have a negative interactive effect on COVID-19 transmission, implying that rising temperature restrains the facilitating effects of air pollution and that they jointly lead to a decrease in new confirmed cases.
Verdict: Refutes
Question: how does the coronavirus respond to changes in the weather
Claim: outbreaks of the new coronavirus will wane as winter turns to spring
Evidence: We show that the delay between exposure and detection of infection complicates the estimation of weather impact on COVID-19 transmission, potentially explaining significant variability in results to-date
Verdict: Neutral
Evidence: Preliminary observations from our team and others suggest that temperature and climatological factors could influence the spread of this novel coronavirus
Verdict: Supports
Evidence: temperature is the most influential parameter that reduces the growth at the rate of 13-17 cases/day with a 1C rise in temperature.
Verdict: Supports
Evidence: Temperature is the most influential parameter that reduces the growth at the rate of 13-16 cases/day with a 1{degrees}C rise in temperature
Verdict: Supports
Question: How much impact do masks have on preventing the spread of the COVID-19?
Claim: masks can not slow the spread of coronavirus
Evidence: Model simulations, using data relevant to COVID-19 dynamics in the US states of New York and Washington, suggest that broad adoption of even relatively ineffective face masks may meaningfully reduce community transmission of COVID-19 and decrease peak hospitalizations and deaths.
Verdict: Refutes
Evidence: Our simple model shows that modest efficacy of masks could avert substantial mortality in this scenario. Importantly, the effects on mortality became hyper-sensitive to mask-wearing as the effective R approaches 1, i.e. near the tipping point of when the infection trajectory is expected to revert to exponential growth, as would be expected after effective lockdown. Our model suggests that mask-wearing might exert maximal benefit as nations plan their post-lockdown strategies and suggests that mask-wearing should be included in further more sophisticated models of the current pandemic.
Verdict: Refutes
Evidence: We make 3 key observations: 1. Masks, even with suboptimal efficacy in both prevention of acquisition and transmission of infection, could substantially decrease the reproduction number for COVID-19 if widely used. 2. Widespread masking may be sufficient to suppress epidemics where R has been brought close to 1 via other measures (e.g., distancing). 3. Assortment within populations (the tendency for interactions between masked individuals to be more likely than interactions between masked and unmasked individuals) would rapidly erode the impact of masks.
Verdict: Refutes
Evidence: Depending on the region we analyse, we find that face masks reduced the cumulative number of registered Covid-19 cases between 2.3% and 13% over a period of 10 days after they became compulsory. Assessing the credibility of the various estimates, we conclude that face masks reduce the daily growth rate of reported infections by around 40%.
Verdict: Refutes
Question: Can taking medication to lower fever, such as paracetamol (tylenol) and ibuprofen (advil) worsen COVID-19?
Claim: the use of ibuprofen and similar anti-inflammatory drugs could be "an aggravating factor" in COVID-19 infections
Evidence: As fever may have benefit in shortening the duration of viral illness, it is plausible to hypothesize that the antipyretic efficacy of ibuprofen may be hindering the benefits of a fever response when taken during the early stages of COVID-19 illness.
Verdict: Refutes
Evidence: When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen.
Verdict: Refutes
Evidence: When compared to exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen.
Verdict: Refutes
Evidence: For NSAIDs, there is no clear scientific evidence linking ibuprofen and other NSAIDs to worsening of COVID-19;
Verdict: Refutes
Question: Can animals spread COVID-19 to people?
Claim: Further studies are needed to understand if and how different animals could be affected by the virus and the role animals may play in the spread of COVID-19.
Evidence: Coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is now a pandemic threat. This virus is supposed to be spread by human to human transmission. 
Verdict: Supports
Evidence: There are now many reports of SARS-CoV-2 positive cases in dogs, cats, tigers, lion, and minks. Experimental data showed ferrets and cats are highly susceptible to SARS-CoV-2 as infected by virus inoculation and can transmit the virus directly or indirectly by droplets or airborne route.
Verdict: Supports
Evidence: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--the virus that causes coronavirus disease (COVID-19)--has been detected in domestic dogs and cats, raising concerns of transmission from, to, or between these animals. There is currently no indication that feline- or canine-to-human transmission can occur, though there is rising evidence of the reverse.
Verdict: Supports
Evidence: ferrets and cats are highly susceptible to SARS-CoV-2 as infected by virus inoculation and can transmit the virus directly or indirectly by droplets or airborne routes.
Verdict: Supports
Question: what kinds of complications related to COVID-19 are associated with hypertension?
Claim: Having other cardiovascular or cerebrovascular disease, such as hypertension (high blood pressure) or stroke, may increase your risk of severe illness from COVID-19.
Evidence: Hypertension was associated with increased composite poor outcome, including mortality, severe COVID-19, ARDS, need for ICU care and disease progression in patients with COVID-19.
Verdict: Supports
Evidence:  Hypertension has been proven to be more prevalent in patients with an adverse outcome (admission in intensive care unit, use of mechanical ventilation, or death).
Verdict: Supports
Evidence: COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8+ cells on admission. Patients with hypertension were more likely to have comorbidities and complications and were more likely to be classified as critically ill than those without hypertension.
Verdict: Supports
Evidence: obesity represents the strongest predictor for Covid-19 followed by diabetes and hypertension in both sexes
Verdict: Supports
Question: Does Vitamin D impact COVID-19 prevention and treatment?
Claim: Taking vitamin D supplement can reduce the risk of becoming infected with COVID-19.
Evidence: A significant negative correlation (p=0.033) has been observed between mean vitamin D levels and COVID-19 cases per one million population in European countries.
Verdict: Supports
Evidence: ecological investigation on 51 countries including 408,748 participants, analyses indicated no correlation between vitamin D levels and recovery rate (r= 0.041) as well as mortality rate (r=-0.073) globally.
Verdict: Refutes
Evidence: Several studies demonstrated the role of vitamin D in reducing the risk of acute viral respiratory tract infections and pneumonia. These include direct inhibition with viral replication or with anti-inflammatory or immunomodulatory ways. In the meta-analysis, vitamin D supplementation has been shown as safe and effective against acute respiratory tract infections. Thus, people who are at higher risk of vitamin D deficiency during this global pandemic should consider taking vitamin D supplements to maintain the circulating 25(OH)D in the optimal levels (75-125nmol/L).
Verdict: Supports
Evidence: A principal defence against uncontrolled inflammation, and against viral infection in general, is provided by T regulatory lymphocytes (Tregs). Treg levels have been reported to be low in many COVID-19 patients and can be increased by vitamin D supplementation. Low vitamin D levels have been associated with an increase in inflammatory cytokines and a significantly increased risk of pneumonia and viral upper respiratory tract infections. Vitamin D deficiency is associated with an increase in thrombotic episodes, which are frequently observed in COVID-19. Vitamin D deficiency has been found to occur more frequently in patients with obesity and diabetes. These conditions are reported to carry a higher mortality in COVID-19. If vitamin D does in fact reduce the severity of COVID-19 in regard to pneumonia/ARDS, inflammation, inflammatory cytokines and thrombosis, it is our opinion that supplements would offer a relatively easy option to decrease the impact of the pandemic.
Verdict: Supports
Question: what is the origin of COVID-19
Claim: 5G mobile networks do not cause or spread COVID-19.
Evidence: The COVID19, which appeared to originate in China in December 2019, has spread worldwide pandemically.
Verdict: Neutral
Evidence: Recent research results suggest that bats or pangolins might be the original hosts for the virus based on comparative studies using its genomic sequences.
Verdict: Supports
Evidence: The results obtained from various AI-enabled experiments using clustering algorithms demonstrate that all examined COVID-19 virus genomes belong to a cluster that also contains bat and pangolin coronavirus genomes.
Verdict: Supports
Evidence: Although to date it is considered that Covid19 originates from bats (96.2% overall genome sequence identity) (1), the type of intermediate animals that caused the transmission to humans remains unknown (2-4).
Verdict: Supports
Question: How much impact do masks have on preventing the spread of the COVID-19?
Claim: Masks include the ones that are made at home (typically cloth masks, made out of T-shirts and the like) as well as other non-medical and non-N95 masks are effective in limiting the spread of covid-19
Evidence: Depending on the region we analyse, we find that face masks reduced the cumulative number of registered Covid-19 cases between 2.3% and 13% over a period of 10 days after they became compulsory. Assessing the credibility of the various estimates, we conclude that face masks reduce the daily growth rate of reported infections by around 40%.
Verdict: Supports
Evidence: Our simple model shows that modest efficacy of masks could avert substantial mortality in this scenario. Importantly, the effects on mortality became hyper-sensitive to mask-wearing as the effective R approaches 1, i.e. near the tipping point of when the infection trajectory is expected to revert to exponential growth, as would be expected after effective lockdown. Our model suggests that mask-wearing might exert maximal benefit as nations plan their post-lockdown strategies and suggests that mask-wearing should be included in further more sophisticated models of the current pandemic.
Verdict: Supports
Evidence: Model simulations, using data relevant to COVID-19 dynamics in the US states of New York and Washington, suggest that broad adoption of even relatively ineffective face masks may meaningfully reduce community transmission of COVID-19 and decrease peak hospitalizations and deaths.
Verdict: Supports
Evidence: COVID-19, caused by SARS-CoV2 is a rapidly spreading global pandemic. Although precise transmission routes and dynamics are unknown, SARS-CoV2 is thought primarily to spread via contagious respiratory droplets.
Verdict: Neutral
Question: Can face masks protect me from the coronavirus disease?
Claim: Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19
Evidence: 2) addresses controversies surrounding the mask from perspectives of attitude, effectiveness, and necessity of wearing the mask with evidence that the use of mask would effectively interrupt the transmission of infectious diseases in both hospital settings and community settings;
Verdict: Supports
Evidence: In this study, we demonstrated, using avian coronavirus of infectious bronchitis virus to mimic SARSCoV2, that medical masks and N95 masks remained their blocking efficacy after being steamed on boiling water even for 2 hours.
Verdict: Supports
Evidence: We also demonstrated that three brands of medical masks blocked over 99% viruses in aerosols. The avian coronavirus was completely inactivated after being steamed for 5 minutes.
Verdict: Supports
Evidence: Together, this study suggested that medical masks are adequate for use on most social occasions, and both medical masks and N95 masks can be reused for a few days with steam decontamination between use.
Verdict: Supports
Question: Can 5G technology cause COVID-19?
Claim: There is no scientific evidence that 5G towers are causing COVID-19 symptoms or that 5G radiation is making people more susceptible to SARS-CoV2 infections.
Evidence: Content analysis revealed that, of 233 sample tweets, 34.8% (n=81) contained views that 5G and COVID-19 were linked
Verdict: Refutes
Evidence: 5G-based robot-assisted remote ultrasound system is feasible, and effectively obtains ultrasound characteristics for cardiopulmonary assessment of COVID-19 patients.
Verdict: Supports
Evidence: The aim of this study is to develop an understanding of the drivers of the 5G COVID-19 conspiracy theory and strategies to deal with such misinformation. 
Verdict: Supports
Evidence: 5G communication technology has the characteristics of faster speed, shorter time delay and denser capacity. In COVID-19 epidemic prevention and control work, it can further improve the efficiency of doctors&apos; diagnosis, improve patients&apos; medical experience, realize the remote sharing of high-quality medical resources and real-time information exchange, effectively block the spread of epidemic, alleviate the shortage of medical resources and medical staff, and make the epidemic prevention and control more efficient.
Verdict: Supports
Question: Does Vitamin C impact COVID-19 prevention and treatment?
Claim: vitamin C deficiency is related to the increased risk and severity of influenza infections.
Evidence: Although COVID-19 can be rapidly diagnosed, efficient clinical treatment of COVID-19 remains unavailable, resulting in high fatality.
Verdict: Neutral
Evidence: The majority of documents encouraged the consumption of fruits, vegetables, and whole grain foods. Thirty-one percent of the guidelines highlighted the importance of minerals and vitamins such as zinc and vitamins C, A, and D to maintain a well-functioning immune system.
Verdict: Neutral
Evidence: CONCLUSION The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.
Verdict: Neutral
Evidence: Dietary supplementation has not been linked to COVID-19 prevention.
Verdict: Neutral
Question: Does Vitamin C impact COVID-19 prevention and treatment?
Claim: vitamin D can play in helping a patient fight off COVID-19.
Evidence: Dietary supplementation has not been linked to COVID-19 prevention. However, supplementation with vitamins C and D, as well as with zinc and selenium, was highlighted as potentially beneficial for individuals with, or at risk of, respiratory viral infections or for those in whom nutrient deficiency is detected.
Verdict: Supports
Evidence: CONCLUSION The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.
Verdict: Neutral
Evidence: Although COVID-19 can be rapidly diagnosed, efficient clinical treatment of COVID-19 remains unavailable, resulting in high fatality.
Verdict: Refutes
Evidence: Dietary supplementation has not been linked to COVID-19 prevention.
Verdict: Refutes
Question: are there any drugs that work for SARS-CoV or SARS-CoV-2 in animals?
Claim: the drug pixatimod is a potent inhibitor of SARS-CoV-2 viral attachment and invasion in Vero cell culture, with a reduction of cytopathic effect when applied at concentrations within the established therapeutic concentrations.
Evidence: Thus, our goal is to test the most active antivirals identified in adequate animal models infected with SARS-CoV-2, to add more information about possible in vivo efficacy. In turn, successful antivirals could be tested in clinical trials as treatments for infected patients, but also as pre-exposure prophylaxis to avoid novel infections until an effective and safe vaccine is developed.
Verdict: Neutral
Evidence: We show that a high (5106 pfu) and medium (5104 pfu) dose of SARS-CoV-2 induces consistent upper respiratory tract (URT) viral RNA shedding in both groups of six challenged animals, whilst a low dose (5102 pfu) resulted in only one of six displaying signs of URT viral RNA replication.  
Verdict: Neutral
Evidence: We show that a high (5106 pfu) and medium (5104 pfu) dose of SARS-CoV-2 induces consistent upper respiratory tract (URT) viral RNA shedding in both groups of six challenged animals, whilst a low dose (5102 pfu) resulted in only one of six displaying signs of URT viral RNA replication.  
Verdict: Neutral
Evidence: When used for prophylaxis or treatment neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. In conclusion, our preclinical animal studies do not support the use of HCQ in prophylaxis/treatment of COVID-19.
Verdict: Neutral
Question: How much impact do masks have on preventing the spread of the COVID-19?
Claim: disposable ear loop masks do not provide any protection against the novel coronavirus.
Evidence: Our results suggest use of face masks by the general public is potentially of high value in curtailing community transmission and the burden of the pandemic. The community-wide benefits are likely to be greatest when face masks are used in conjunction with other non-pharmaceutical practices (such as social-distancing), and when adoption is nearly universal (nation-wide) and compliance is high.
Verdict: Refutes
Evidence: We present two models for the COVID-19 pandemic predicting the impact of universal face mask wearing upon the spread of the SARS-CoV-2 virus--one employing a stochastic dynamic network based compartmental SEIR (susceptible-exposed-infectious-recovered) approach, and the other employing individual ABM (agent-based modelling) Monte Carlo simulation--indicating (1) significant impact under (near) universal masking when at least 80% of a population is wearing masks, versus minimal impact when only 50% or less of the population is wearing masks, and (2) significant impact when universal masking is adopted early, by Day 50 of a regional outbreak, versus minimal impact when universal masking is adopted late. 
Verdict: Refutes
Evidence: Notably, masks are found to be useful with respect to both preventing illness in healthy persons and preventing asymptomatic transmission. Hypothetical mask adoption scenarios, for Washington and New York state, suggest that immediate near universal (80%) adoption of moderately (50%) effective masks could prevent on the order of 17--45% of projected deaths over two months in New York, while decreasing the peak daily death rate by 34--58%, absent other changes in epidemic dynamics. Even very weak masks (20% effective) can still be useful if the underlying transmission rate is relatively low or decreasing: In Washington, where baseline transmission is much less intense, 80% adoption of such masks could reduce mortality by 24--65% (and peak deaths 15--69%), compared to 2--9% mortality reduction in New York (peak death reduction 9--18%).
Verdict: Refutes
Evidence: Our simple model shows that modest efficacy of masks could avert substantial mortality in this scenario. Importantly, the effects on mortality became hyper-sensitive to mask-wearing as the effective R approaches 1, i.e. near the tipping point of when the infection trajectory is expected to revert to exponential growth, as would be expected after effective lockdown. Our model suggests that mask-wearing might exert maximal benefit as nations plan their post-lockdown strategies and suggests that mask-wearing should be included in further more sophisticated models of the current pandemic.
Verdict: Refutes
Question: will SARS-CoV2 infected people develop immunity?
Claim: T cells may help COVID-19 patients - and people never exposed to the virus
Evidence: The number of these epitopes and the prevalence of the common coronaviruses suggest that a large part of the world population has some degree of specific immunity against SARS-CoV-2 already, even without having been infected by that virus.
Verdict: Neutral
Evidence: The number of these epitopes and the prevalence of the common coronaviruses suggest that a large part of the world population has some degree of specific immunity against SARS-CoV-2 already, even without having been infected by that virus.
Verdict: Neutral
Evidence: The CD4 + memory exploiting could help immune system to recall immunity of already know antigens against coronaviruses, avoiding or limiting "lung crash" until virus specific immunity develops and making it faster and prolonged. Finally, this administration could be helpful not only in already infected patients, but also before infection. In fact, people could have an immune system more ready when the contact with the Covid-19 will occur.
Verdict: Neutral
Evidence: we discovered evidence that SARS-CoV-2, along with related coronaviruses, used mutations to evade attack from the human immune system. Overall, we present an immunological resource for SARS-CoV-2 that could promote both therapeutic development and mechanistic research.
Verdict: Neutral